B
Bull
Bull · 25%KLRS
$2.74
Precio del escenario
$4.030
-0.069 (-1.71%)Al cierre
Loading chart…
- High
- 4.150
- Open
- 4.120
- VWAP
- 4.02
- Vol
- 52.61K
- Mkt Cap
- —
- Low
- 3.890
- Amount
- 211.68K
- EV/EBITDA, TTM
- 0.00
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
AI analysis of Kalaris Therapeutics Inc (KLRS)
buyKalaris Therapeutics is a good buy right now due to its recent positive clinical trial results for TH103, which showed significant improvements in vision and retinal anatomy, indicating strong potential for future growth. The stock is currently priced at $4.03, significantly lower than analyst targets of $17 and $25, suggesting a substantial upside potential. Additionally, the RSI is at 44.112, indicating the stock is not overbought, and the recent appointment of a new CFO may help stabilize the company's financial performance. However, the main risk is the ongoing negative net income, with losses reaching -11,515,000 USD in Q2 2026, which investors should monitor closely.
Métricas de valoración
The current forward P/E ratio for Kalaris Therapeutics Inc (KLRS) is 0.00, compared to its 5-year average forward P/E of -1.86.
Alphio AI Price Scenarios for KLRS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding KLRS
Cronología de eventos
Noticias
7.008-04NewsfilterInvestigation into Kalaris Therapeutics Shareholder Claims
5.007-20seekingalphaKalaris Therapeutics Appoints New CFO
9.007-17NASDAQ.COMKalaris Therapeutics Reports Positive Phase 1a Data for TH103 in Retinal Diseases
9.007-17NASDAQ.COMKalaris Therapeutics Reports Positive Phase 1a Data for TH103 in AMD
- 2.007-17Newsfilter
Kalaris Reports Positive Data for TH103 in AMD Treatment
KLRS FAQ — answered by Alphio AI
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO). It operates in the Healthcare sector.
Kalaris Therapeutics is a good buy right now due to its recent positive clinical trial results for TH103, which showed significant improvements in vision and retinal anatomy, indicating strong potential for future growth. The stock is currently priced at $4.03, significantly lower than analyst targets of $17 and $25, suggesting a substantial upside potential. Additionally, the RSI is at 44.112, indicating the stock is not overbought, and the recent appointment of a new CFO may help stabilize the company's financial performance. However, the main risk is the ongoing negative net income, with losses reaching -11,515,000 USD in Q2 2026, which investors should monitor closely.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.